Abcam’s multiplex immunoassays combine unique Firefly ® hydrogel technology with Abcam’s high-performance antibodies to simultaneously measure up to 75 different proteins in a mere 12.5 µL of sample.

Abcam plc has entered into a definitive agreement to acquire the entire issued share capital of Firefly BioWorks Inc ("Firefly") on a cash-free/debt-free basis for £18.5m ($28.0m). The consideration, ...

The Firefly G3 system delivers unique inspection and metrology process control technologies aimed at buried defects and voids supporting next generations of glass and copper clad laminate (CCL) The ...

Life science tools supplier Abcam will pay £18.5 million ($28 million) cash to acquire Firefly BioWorks, the developer of a multiplex assay platform for biomarker detection. Developed by the company’s ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Firefly BioWorks, Inc., a manufacturer of universally compatible multiplex assays, announced today it was awarded a $2M Phase II Small Business Innovation Research ...

The new multiplex immunoassays combine Firefly® hydrogel technology with their high-performance antibodies to simultaneously measure up to 75 different proteins in a mere 12.5 µL of sample. With ...

WILMINGTON, Mass.--(BUSINESS WIRE)--Rudolph Technologies, Inc. (NYSE: RTEC) announced today that two of the industry’s leading suppliers of advanced packaging services have purchased multiple Firefly™ ...